All PlansPrior AuthMedium impact
Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza™)
BCBS Tennessee·TN · Oncology, Hematology·Medical Policy
Effective date
Jun 30, 2026
We identified it
Jun 17, 2026
Summary
BlueCross BlueShield Tennessee is implementing a new medical policy for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), a subcutaneous cancer immunotherapy drug. The policy establishes prior authorization requirements and coverage criteria for multiple cancer types including lung cancer, hepatocellular carcinoma, melanoma, and others, with 6-month authorization periods.
Action Required
Before June 30, 2026: Billing and prior authorization teams must prepare workflows for Tecentriq Hybreza™ prior authorizations. Update systems to require PD-L1 testing results, BRAF mutation testing, and EGFR/ALK aberration testing documentation where applicable. Train staff on the specific coverage criteria for each cancer type and 6-month authorization limits. Set up denial protocols for patients with disease progression on prior PD-1/PD-L1 inhibitor therapy.